Kava dermopathy in Fiji: An acquired ichthyosis?

International Journal of Dermatology

Volumn 53, Issue 12, 2014, Pages 1490-1494

  Hannam, Sarah ^a   Murray, Michael ^b   Romani, Lucia ^c   Tuicakau, Meciusela ^d   Whitfeld, Margot J ^e,f  

^a SKIN AND CANCER FOUNDATION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Ministry of Health   (Fiji)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; KAVA; CYTOCHROME P450; LACTONE;

ARTICLE; CLINICAL FEATURE; FIJI; HUMAN; ICHTHYOSIS; KAVA DERMOPATHY; LAMELLAR ICHTHYOSIS; MOLECULAR PATHOLOGY; NONHUMAN; BEVERAGE; CHEMISTRY; EPIDERMIS; GENETICS; PATHOLOGY; PHYTOTHERAPY;

BEVERAGES; CYTOCHROME P-450 ENZYME SYSTEM; EPIDERMIS; FIJI; HUMANS; ICHTHYOSIS; KAVA; LACTONES; PHYTOTHERAPY;

EID: 84914122693     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12546     Document Type: Article

References (40)

1. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31: 89-97.
2. Lebot V. Kava (Piper methysticum Forst f.). The Polynesian dispersal of an Oceania plant. In: Cox PA, Bannack SA, eds. Islands, Plants and Polynesians: an Introduction to Polynesian Ethnobotany. Portland: Dioscorides Press, 1991: 169-201.
3. KAVA. A Human Health Risk Assessment. Technical Report Series No. 30. Food Standards Australia New Zealand. June 2004.
4. Lebot V, Cabalion P. Kavas of Vanuatu: Cultivars of Piper methysticum Forst. Technical Paper No. 195, 1998. South Pacific Commission, Noumea.
5. Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Derm 2000; 42: 364.
6. Suss R, Lehmann P. Hematogenous contact eczema caused by phytogenic drugs exemplified by kava root extract. Hautarzt 1996; 47: 459-461.
7. Siegel RK. Herbal intoxication. JAMA 1976; 23: 473-476.
8. Shulgin AT. The narcotic pepper: The chemistry and pharmacology of methysticum and related species. Bull Narc 1973; 25: 59-74.
9. Jappe U, Franke I, Reinhold D, et al. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 1998; 38: 104-106.
10. Frater AS. Medical aspects of yaqona. Trans Proc Fijian Soc 1958; 5: 31-39.
11. Singh YN. Kava: an overview. J Ethnopharmacol 1992; 37: 13-45.
12. Rychetnic L, Madrano CM. The health and social effects of drinking water-based infusions of kava: A review of the evidence. Drug Alcohol Rev 2011; 30: 74-83.
13. Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 2011; 45: 27-34.
14. Cawte J. Macabre effects of a "cult" for kava. Med J Aust 1988; 148: 545-546.
15. Clough A. Enough! Or too much. What is "excessive" kava use in Arnhem Land? Drug Alcohol Rev 2003; 22: 43-51.
16. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003; CD003383.
17. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003; CD003383.
18. Abbott T, Johnston D. Kava importation into Australia. Joint release by The Hon Tony Abbott MHR, Minister for Health and Ageing and Senator the Hon David Johnston, Minister for Justice and Customs. 2007 Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/importation-of-kava [accessed 09/11/12].
19. Ulbricht C, Basch E, Boon H, et al. Safety review of kava (Piper methysticum) by Natural Standard Research Collaboration. Expert Opin Drug Saf 2005; 4: 779-794.
20. Palmer VS, Jain SC, Bisht KS, et al. Phytochemistry of the genus Piper. Phytochemistry 1997; 64: 597-673.
21. Murray M. Toxicological actions of plant-derived and anthropogenic methylenedioxyphenyl substituted chemicals in mammals and insects. J Toxicol Environ Health B Crit Rev 2012; 15: 365-395.
22. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69.
23. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002; 16: 731-743.
24. Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 2002; 70: 2581-2597.
25. Mathews JM, Etheridge AS, Valentine JL, et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 2005; 33: 1555-1563.
26. Clough AR, Jacups SP, Wang Z, et al. Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern Med J 2003; 33: 336-340.
27. Lebot V, Merlin M, Linstrom L. Kava the Pacific Drug. New Haven, CT: Yale University Press, 1992: 10.
28. Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet 1990; 335: 1442-1445.
29. Shimoda LM, Park C, Stokes AJ, et al. Pacific Island 'Awa (Kava) extracts, but not isolated kavalactones, promote proinflammatory responses in model mast cells. Phytother Res 2012; 26: 1934-1941.
30. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440-452.
31. Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 2004; 5: 17-29.
32. Kohda F, Koga T, Uchi H, et al. Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes. J Dermatol Sci 2002; 28: 34-41.
33. Harvima IT, Nilsson G, Suttle MM, et al. Is there a role for mast cells in psoriasis? Arch Dermatol Res 2008; 300: 461-478.
34. Kelly EJ, Nakano M, Rohatgi P, et al. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Mol Interv 2011; 11: 124-132.
35. Vahlquist A. Pleomorphic ichthyosis: proposed name for a heterogeneous group of congenital ichthyoses with phenotypic shifting and mild residual scaling. Acta Derm Venereol 2010; 90: 454-460.
36. Lefevre C, Bouadjar B, Ferrand V, et al. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 2006; 15: 767-776.
37. Nilsson T, Ivanov IV, Oliw EH. LC-MS/MS analysis of epoxyalcohols and epoxides of arachidonic acid and their oxygenation by recombinant CYP4F8 and CYP4F22. Arch Biochem Biophys 2010; 494: 64-71.
38. Shibaki A, Akiyama M, Shimizu H. Novel ALDH3A2 heterozygous mutations are associated with defective lamellar granule formation in a Japanese family of Sjögren-Larsson syndrome. J Invest Dermatol 2004; 123: 1197-1199.
39. Mathews JM, Etheridge AS, Black SR. Inhibition of P450 enzymes by kava extract and kavalactones. Drug Metab Dispos 2003; 30: 1153-1157.
40. Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14: 1-18.
41. Patel N, Spencer LA, English JC. Acquired ichthyosis. J Am Acad Dermatol 2006; 55: 647-656.